Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating compounds in Phase II and Phase III clinical development worldwide. New Phase II data results for linagliptin (BI 1356), a dipeptidyl peptidase 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American Diabetes Association (ADA) Scientific Sessions in New Orleans.

"Type 2 diabetes is a growing public health concern," said J. Martin Carroll, Boehringer Ingelheim USA Corporation president and CEO. "Our Company will draw from its knowledge and experience to help us deliver on the much needed treatment options for patients who are living with the disease. Boehringer Ingelheim is inspired to make a difference in diabetes care."

Results from the Phase II study presented at ADA show that 1, 5 and 10 mg doses of linagliptin achieved clinically relevant and statistically significant reductions in HbA1c, a measure of blood sugar, when given as add-on therapy to type 2 diabetes patients inadequately controlled on metformin (placebo-corrected changes from baseline; -0.40 percent for the 1 mg dose, -0.73 percent for the 5 mg dose, and -0.67 percent for the 10 mg dose).(1) The most frequently reported adverse events in patients treated with all doses of linagliptin compared to placebo were nasopharyngitis, (7.1 vs. 9.9 percent) diarrhea (2.5 vs. 4.2 percent) and nausea (3.5 vs. 4.2 percent). No cases of hypoglycemia were reported in patients receiving linagliptin.(1)

"Many patients don't achieve adequate blood sugar control with commonly used diabetes medications like metformin. The significant reduction in HbA1c levels seen in this trial is encouraging as it indicates linagliptin may have a potential role in t
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group finds ... growth factor (VEGF) agent for wet AMD, is equally ... plans as Genentech,s Lucentis, which is the standard of ... care organization (MCO) directors do not identify a clear ... more likely than Lucentis to be listed on tier ...
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and Drug Administration (FDA) has removed the clinical ... in SWOG,s ongoing Phase 1b/2 clinical trial (S1313). ... drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination ... metastatic pancreatic adenocarcinoma.  The study will resume under ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
(Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... can quickly alter the way brain cells communicate with one ... Sept. 18 in Current Biology , are a step ... Experts said the hope is to eventually be able to ... a drug -- and which people would fare better with ...
(Date:9/18/2014)... of Chest Physicians (CHEST) together with the Chinese ... congress of CTS that CHEST World Congress 2016 ... pulmonary, critical care, and sleep medicine from around ... event, slated for spring 2016. , CHEST ... including hands-on simulation training, keynote addresses, presentations by ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... 2014 Stealth Health Revolution co-founders, ... and Frank Davis, founder of Food for Health ... pleased to announce the new recipe book, "The ... nutrition-packed meals using Activz whole-food powders." The ... in the Stealth Health Revolution mission ...
Breaking Medicine News(10 mins):Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... FRIDAY, Feb. 17 (HealthDay News) -- Knees with osteoarthritis are ... are not, researchers say. The discovery was a surprise, ... and immunology at Duke University Medical Center in Durham, N.C. ... we didn,t know about and the main treatment strategy probably ...
... researchers are expressing concern about a new, under-recognized, much ... surfaced in the U.S. "Historically, in Western countries, ... have caused infections mostly in sick, hospitalized patients whose ... professor in the Department of Medicine at the UB ...
... the job in the U.S. each year, and millions more ... a worker,s perception of safety in the workplace and the ... on-the-job injury. "We,ve known for some time that certain ... of physical and other hazards," said Dave DeJoy, UGA professor ...
... the pioneering days of the juvenile corrections system, social ... rehabilitated young offenders. As the field of corrections became ... workers was marginalized. A University of Missouri expert on ... return to the juvenile corrections system and reclaim their ...
... Esposito HealthDay Reporter , FRIDAY, Feb. 17 ... good helmet fit might help reduce loss of consciousness ... new study finds. Expensive, high-tech helmets with air-lining ... concussions, the researchers said. "The occurrence of concussion ...
Cached Medicine News:Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Arthritic Hip May Be Tougher to Treat Than Knee 2Health News:Nasty 'superbug' is being studied by UB researchers 2Health News:Nasty 'superbug' is being studied by UB researchers 3Health News:Perception, work-life balance key factors in workplace safety, says UGA study 2Health News:Perception, work-life balance key factors in workplace safety, says UGA study 3Health News:Social workers should reclaim role in juvenile corrections system, MU researcher says 2Health News:Good Football Helmet Fit Key to Preventing Brain Injuries 2Health News:Good Football Helmet Fit Key to Preventing Brain Injuries 3
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Only Mobile Instrument offers complete repair and rebuild capability on all makes and models of endoscopy and laparoscopy instruments, using only factory-quality parts and precision techniques....
... Broken, burnt or damaged fiber optics reduce the ... a substantial decrease in the optical clarity that ... optic instrumentation is essential to prevent further damage ... Mobile Instrument technician can inspect your cables for ...
... camera upon arrival.,Our technician then makes note of ... a thorough customer quote. We respect that you ... well help you prioritize repairs. With customer approval, ... ISI uses only OEM or widely approved equivalent ...
Medicine Products: